Cover Image
市場調查報告書

生殖器濕疣 (尖頭濕疣):開發中產品分析

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 200950
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
生殖器濕疣 (尖頭濕疣):開發中產品分析 Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016
出版日期: 2016年04月30日 內容資訊: 英文 70 Pages
簡介

生殖器濕疣(尖頭濕疣)是一般最常見的性行為感染疾病之一。積極從事性活動的人半數以上曾在一生中的某個時刻感染到引起生殖器濕疣的病毒。如名字所示,生殖器濕疣會對性器官潮濕的組織起作用。生殖器濕疣的外表,為小型肉色疙瘩的形式(或菜花狀外形)。大多數場合,疙瘩非常小,肉眼無法辨識。

本報告提供全球各國生殖器濕疣 (尖頭濕疣) 治療用之開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

生殖器濕疣 (尖頭濕疣)概要

治療藥的開發

  • 開發中產品的概要

生殖器濕疣 (尖頭濕疣):企業開發中的治療藥

生殖器濕疣 (尖頭濕疣):開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

生殖器濕疣 (尖頭濕疣):企業開發中的產品

生殖器濕疣 (尖頭濕疣的)治療藥的開發企業

  • Agilvax, Inc.
  • Aviragen Therapeutics, Inc.
  • Biogenomics Limited
  • BioMAS Ltd.
  • Foamix Pharmaceuticals Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Helix BioPharma Corp.
  • Laboratories Ojer Pharma S.L.
  • LEO Pharma A/S
  • Novan, Inc.
  • Novartis AG
  • Tamir Biotechnology, Inc.
  • Zydus Cadila Healthcare Limited

生殖器濕疣 (尖頭濕疣):治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

生殖器濕疣 (尖頭濕疣):最近的開發平台趨勢

生殖器濕疣 (尖頭濕疣):暫停中的計劃

生殖器濕疣 (尖頭濕疣):開發中止的產品

生殖器濕疣 (尖頭濕疣):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8046IDB

Summary

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016', provides an overview of the Genital Warts (Condylomata Acuminata) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Warts (Condylomata Acuminata), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
  • The report reviews pipeline therapeutics for Genital Warts (Condylomata Acuminata) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Genital Warts (Condylomata Acuminata) therapeutics and enlists all their major and minor projects
  • The report assesses Genital Warts (Condylomata Acuminata) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Genital Warts (Condylomata Acuminata)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Genital Warts (Condylomata Acuminata) Overview
  • Therapeutics Development
    • Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview
  • Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies
  • Genital Warts (Condylomata Acuminata) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Genital Warts (Condylomata Acuminata) - Products under Development by Companies
  • Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development
    • Agilvax, Inc.
    • Aviragen Therapeutics, Inc.
    • Biogenomics Limited
    • BioMAS Ltd.
    • Foamix Pharmaceuticals Ltd.
    • G&E Herbal Biotechnology Co., Ltd.
    • Helix BioPharma Corp.
    • Laboratories Ojer Pharma S.L.
    • LEO Pharma A/S
    • Novan, Inc.
    • Novartis AG
    • Tamir Biotechnology, Inc.
    • Zydus Cadila Healthcare Limited
  • Genital Warts (Condylomata Acuminata) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cervical cancer + genital warts) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AX-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BTA-074 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ingenol mebutate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alpha-2b (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LFX-453 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PP-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranpirnase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates
  • Genital Warts (Condylomata Acuminata) - Dormant Projects
  • Genital Warts (Condylomata Acuminata) - Discontinued Products
  • Genital Warts (Condylomata Acuminata) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions
      • Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
      • Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
      • Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2016
  • Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2016
  • Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top